🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccination guidelines, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccines during the global health crisis and has focused upon alleged fatalities following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Program

Health officials planned to announce radical revisions to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of step with a large portion of the world with insufficient data for improved outcomes. This reveal has been delayed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to head the center this year.

Consolidating Power at the Agency

This interim role might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for ending certain pediatric vaccine recommendations in the US so as to align more like Denmark, a country with universal health coverage and a population roughly the population of Wisconsin’s.

To date comments, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent background in medication creation, oversight or management, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have the necessary background” for leading the drug-regulation department, said Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She lacks background in industry regulation.”

Previous directors of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that previous people who ran CBER have had.”

The drug center has an immense range of responsibilities at the agency, she stated.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office clears thousands of generic medications. There is also a biologic copycat branch, OTC medication office and more, and all of those must be supervised,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership aspect to the job, which supervises over 5,000 staff members. “It is a enormous administrative position, if you perform it correctly,” she said.

Agency Reaction and Disputed Policies

Regarding concerns about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among agency officials on immunizations, a representative responded that the “questions rely on flawed assumptions”.

“Her resume matches the functions of her job,” the official explained, noting the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a controversial expedited therapy clearance system that allegedly worried her predecessors. “By what process are these therapies being chosen for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the FDA seems to be moving towards laxer regulations of all drugs, with the exception of immunizations.”

Public History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if troubling, track record, Howard have noted. She published a analysis using unconfirmed public submissions to determine the frequency of myocarditis following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccinations are riskier than they are.

Among her “policy goals” for the current government featured changing regulations for recently developed shots and discontinuing “non-essential” vaccines, she stated post-election on a podcast. At the FDA, Dr. Høeg has reportedly proposed barring young men from obtaining COVID-19 vaccinations.

“She is an thorough true believer who starts off with her preconceived notions and works backwards to retrofit the evidence in a highly misleading, dishonest fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow skeptics, {like|